Median Technologies Secures €23.9 Million Capital Increase Amid Expansion Plans

Strategic Insights -

Median Technologies, the manufacturer of the eyonis(r) suite of artificial intelligence (AI) powered Software as a Medical Device for early cancer diagnosis, has successfully completed a capital increase of €23.9 million. This significant funding will enable the company to meet the contractual conditions for a €19 million EIB financing line, extend its cash runway through the fourth quarter of 2026, and potentially beyond. With this capital increase, Median Technologies will be able to drive the commercial launch of its Software as a Medical Device, eyonis(r) LCS, in the United States, while also strengthening its position for the distribution of its eyonis(r) LCS product.

Key Takeaways:

  • Median Technologies raised €23.9 million through a capital increase, targeting institutional and retail investors with a minimum subscription amount of €100,000 per investor.
  • The company exercised an extension clause, adding an additional €1.9 million to the capital increase.
  • The capital increase enables Median Technologies to meet the contractual conditions for a €19 million EIB financing line and extends its cash runway through the fourth quarter of 2026.
  • The funds raised will be used to support the commercial launch of eyonis(r) LCS in the United States, accelerate the development of its proprietary suite of Software as a Medical Device, and finance general corporate needs.
  • The new shares and warrants issued as part of the capital increase will be traded on the Euronext Growth Paris market, with settlement and delivery expected on August 5, 2025.
  • The full exercise of the warrants subscribed as part of the Offering would represent additional gross proceeds of €51.7 million.

Statistics:

  • Total gross proceeds from the capital increase: €23.9 million
  • Number of new shares issued: 14,424,541
  • Price per ABSA: €1.66
  • Issuance premium: 72.3% of the Company's existing share capital on a non-diluted basis
  • Number of warrants subscribed: 14,424,541
  • Theoretical value of each warrant: €0.90 per new ordinary share
  • Exercise price of each new ordinary share: €2.39

Sources:

  • Median Technologies press release
  • Regulation (EU) 2017/1129
  • Autorite des Marches Financiers